To assess the accuracy of the CXCR4-based prognostic risk scoring model (PRSM) for survival prediction in patients with primary GBM, we validated it from different perspectives by Kaplan–Meier survival analysis, ROC, and DCA, respectively. This evidence concerns the gene CXCR4 and glioblastoma.